Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies - PubMed (original) (raw)

Meta-Analysis

Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies

Xiao-Ce Dai et al. BMC Cardiovasc Disord. 2020.

Abstract

Background: Our aim was to determine the relationship between the use of fluoroquinolones and the risk of aortic diseases.

Methods: PubMed, EMBASE and the Web of Science were searched from inception to July 6, 2019, to identify observational studies that evaluated the risk of aortic diseases associated in users of fluoroquinolones compared with nonusers or users of other antibiotics. The primary outcome was the first occurrence of aortic diseases. We used the GRADE approach to rate the strength of evidence. We used the inverse variance method random-effect model to estimate the odds ratios (ORs) with 95% CIs, and statistical heterogeneity was assessed by the I2 statistic.

Results: This meta-analysis enrolled 2,829,385 patients reported the relationship between fluoroquinolones and the risk of aortic diseases. Compared with nonusers or users of other antibiotics, users of fluoroquinolone had a significantly increased risk of aortic diseases (adjusted OR, 2.10; 95% CI, 1.65-2.68; P = .000, I2 = 16.4%). The quality of evidence was moderate, and the number needed to harm (NNH) for aortic diseases among patients was estimated to be 1301.

Conclusions: The fluoroquinolone use in patients significantly increases the risk of new-onset aortic diseases. Clinicians need to pay attention to these severe adverse events when considering fluoroquinolone use.

Keywords: Aortic aneurysm; Aortic dissection; Fluoroquinolones; Meta-analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1

Fig. 1

Selection of observational studies for the meta-analysis

Fig. 2

Fig. 2

The Risk of Aortic Diseases among Fluoroquinolone Users in Comparison to Nonusers or Users of Other Antibiotics

Fig. 3

Fig. 3

The Sensitive Analysis for the Risk of Aortic Diseases

Similar articles

Cited by

References

    1. Michalak K, Sobolewska-Wlodarczyk A. Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications. Oxid Med Cell Longev. 2017;2017:8023935. - PMC - PubMed
    1. Singh S, Nautiyal A. Aortic Dissection and Aortic Aneurysms Associated with Fluoroquinolones: A Systematic Review and Meta-Analysis. Am J Med. 2017;130:1449–57.e9. doi: 10.1016/j.amjmed.2017.06.029. - DOI - PubMed
    1. Sommet A, Benevent J, Rousseau V, et al. What Fluoroquinolones have the highest risk of aortic aneurysm? A case/non-case study in VigiBase(R) J Gen Intern Med. 2019;34:502–503. doi: 10.1007/s11606-018-4774-2. - DOI - PMC - PubMed
    1. Lee CC, Lee MG, Hsieh R, et al. Oral Fluoroquinolone and the risk of aortic dissection. J Am Coll Cardiol. 2018;72:1369–1378. doi: 10.1016/j.jacc.2018.06.067. - DOI - PubMed
    1. Lu N, Hu P, Wang J, et al. Simple renal cysts are associated with 24-month prognosis of patients with type B aortic dissection and hypertension. Can J Cardiol. 2019;35(11):1499–1504. doi: 10.1016/j.cjca.2019.07.631. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources